227 Users Online
Ataxia-Telangiectasia Market - Global Industry Analysis 2015 - 2019 and Opportunity Assessment; 2020 - 2030
Ataxia-Telangiectasia is a rare genetic disease occurring in children. Ataxia denotes uncoordinated movements during walking and Telangiectasia refers to enlarged blood vessels beneath the skin. The veins appear to be red, spread like a spider in Telangiectasia.
Ataxia-Telangiectasia is a genetically inherited disorder occurring from a autosomal recessive trait. It develops when both the parents lack a copy of nonfunctional gene. Affected people are likely to have high amounts of a alpha-fetoprotein (AFP) in their blood. However the effect of this protein in people with
Ataxia-Telangiectasia patients is unknown.
Ataxia-Telangiectasia is a result of a mutation in the ATM gene. This gene is responsible for producing a protein that regulate growth and division of cells. Many other problems associated with Ataxia-Telangiectasia are imbalance while walking, hand coordination, jerky movements, muscle twitching and disturbed nerve functioning. Ataxia-Telangiectasia patients often require wheel chair support from adolescence.
FREE Report Sample is Available
In-depth report coverage is now just a few seconds away
Get FREE Report Sample
Ataxia-Telangiectasia being a rare disease, it is a good platform for developing novel treatment options. Around 1 percent of population in the United States carry one-one each of mutated and normal copy of ATM gene. Investment in research of genetic disorders is growing in the US. Many premium research and academic institutes are conduction research on genetic disorders. Girls and boys are equally affected by Ataxia-Telangiectasia. Hence, Ataxia-Telangiectasia appears a threat to the major population as both genders are at risk. Risk of cancer, mainly blood cancers is also high in patients of Ataxia-Telangiectasia. Rising prevalence of cancer in developed and lower economic regions of the world can contribute towards the growth of the Ataxia-Telangiectasia market.
Ataxia-Telangiectasia has a Potential for new treatments under development and many are currently being tested. This is the major factor contributing to its market growth. Increase in prevalence rate of Ataxia-Telangiectasia combined to other clinical manifestations can drive the growth of the market.
Higher chances of cancer in Ataxia-Telangiectasia patients and treatment of cancer is a major driving factor for its treatment market. However cost of diagnosis especially genetic screening and costly therapies like anti-cancer treatments can be a major setback the Ataxia-Telangiectasia treatment market growth. People in lower economic regions are not awareness of genetic disorders and awareness of Genetic screening is low in these regions. Inappropriate diagnosis can cause a setback to the growth of the Ataxia-Telangiectasia treatment market.
Make This Report Your Own
Take Advantage of Intelligence Tailored to your Business Objective
Get a Customized Version| Based on treatment type |
|
| Based on dose modality |
|
| Based on distribution channels |
|
The Ataxia-Telangiectasia is expected to see a growth in the coming years. This is because of wide treatment portfolio, ongoing research studies and increasing awareness about genetic and neurodegenerative diseases. The occurrence of this disease is 1 in 100000 people worldwide. N-Acetyl-L-Leucine is a USFDA and EMA approved treatment for Ataxia-Telangiectasia. The life expectancy in Ataxia-Telangiectasia patients is upto 25 years and continues to improve with proper treatment. The diagnosis of Ataxia-Telangiectasia is assumed by the combination of clinical features like ataxia, abnormal eye movement movements, postural unsteadiness, and increased infections. Antibiotic treatment is also preferred as a treatment option to cure infections in Ataxia-Telangiectasia. Multiple treatment options available make Ataxia-Telangiectasia treatment market a lucrative opportunity.
Sales Team
Client Partner
Europe is leading in terms of clinical trials going on for Ataxia-Telangiectasia treatment. Intrabio, a biopharma company based in UK, has an ongoing clinical trial of it drug N-Acetyl-L-Leucine in phase 2. The USA and Europe have been so far successful in drug development for rare diseases especially neurodegenerative diseases in. Increasing innovative scientific research, investment for research in the fields of neurodegenerative and other genetic diseases so to significantly improve the lives of patients and their families. Other regions are expected to grow in the Ataxia-Telangiectasia treatment market due to increasing expenditure on healthcare.
Some of the key market players in Ataxia-Telangiectasia treatment market are Sanofi, Intrabio Ltd, Intas Pharmaceuticals Ltd, Sun Pharmaceutical Industries Ltd, Cipla Inc, Eli Lilly and Company, Saol Therapeutics Inc, and USV Private Limited.
The research report on Ataxia-Telangiectasia presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, and statistically supported and industry-validated market data. It also contains projections using a suitable set of assumptions and methodologies. The research report on Ataxia-Telangiectasia provides analysis and information according to market segments such as geographies, application, and industry.
The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.
